Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,237 across all filing types
Latest filing 2025-09-30 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges informing about the closure of the trading window pursuant to insider trading regulations. It mentions the upcoming announcement of unaudited financial results for the quarter and half year ended September 30, 2025, but does not contain any financial data or the results themselves. The document is short (2067 characters) and serves as a notification related to trading restrictions ahead of financial results disclosure. This fits the profile of a Regulatory Filing (RNS) as it is a compliance announcement rather than a financial report or earnings release.
2025-09-30 English
Please find enclosed herewith the intimation regarding the Closure of Trading Window.
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges about the closure of the trading window for insiders and designated persons. It references the upcoming announcement of unaudited financial results for the quarter and half year ended September 30, 2025, but does not contain any financial data or results itself. The purpose is to inform about insider trading restrictions ahead of the financial results announcement. The document length is short (2034 characters) and it is clearly an announcement related to trading restrictions, not a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2025-09-30 English
We would like to inform you that the Board has considered and approved the appointment of Mr. Narsimha Shibroor Kamath, Promoter of the Company as the Chief Executive Officer of the Company.
Board/Management Information Classification · 95% confidence The document is a formal communication addressed to stock exchanges (NSE and BSE) regarding the outcome of a Board Meeting held on September 30, 2025. The key content is the announcement of the appointment of Mr. Narsimha Shibroor Kamath as Chief Executive Officer of the company, Bliss GVS Pharma Limited, effective from the same date. The document includes a brief profile of the appointee and details about the appointment. There are no financial statements, earnings data, or detailed management discussion. The document is clearly an announcement of a change in senior management, which fits the category of Board/Management Information (MANG). The document length is 2870 characters, which is typical for such announcements and not a full report. Therefore, the correct classification is MANG with high confidence.
2025-09-30 English
We would like to inform you that the Board has considered and approved the appointment of Mr. Narsimha Shibroor Kamath, Promoter of the Company, as Chief Executive Officer of the Company ....
Board/Management Information Classification · 100% confidence The document is a formal communication addressed to stock exchanges (National Stock Exchange of India and BSE Limited) reporting the outcome of a Board Meeting held on September 30, 2025. The key content is the appointment of Mr. Narsimha Shibroor Kamath as Chief Executive Officer of the company, including his brief profile and relationship disclosures. The document references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30 and Schedule III, which pertain to disclosures about board and management changes. The document is not a full report but an announcement of a management change. It does not contain financial data, earnings, or detailed reports but focuses on board/management information. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 2870 characters, which is short and consistent with an announcement rather than a full report.
2025-09-30 English
Appointment
Board/Management Information Classification · 100% confidence The document is a formal letter addressed to stock exchanges (National Stock Exchange of India and BSE Limited) reporting the outcome of a Board Meeting held on September 30, 2025. The key content is the appointment of Mr. Narsimha Shibroor Kamath as Chief Executive Officer of the company, Bliss GVS Pharma Limited, effective from the same date. The document includes a brief profile of the appointee and disclosures about relationships between directors. There are no financial statements, earnings data, or detailed management discussion. The document is an announcement of a board management change, consistent with filings that disclose changes in senior management or board of directors. The document length is 2870 characters, which is relatively short and typical for such announcements. Therefore, the appropriate classification is Board/Management Information (MANG).
2025-09-30 English
Outcome of Board Meeting
Board/Management Information Classification · 95% confidence The document is a formal letter addressed to the National Stock Exchange of India and BSE Limited, reporting the outcome of a Board Meeting held on September 30, 2025. The key content is the appointment of Mr. Narsimha Shibroor Kamath as Chief Executive Officer of the company, Bliss GVS Pharma Limited, effective from the same date. The document includes details about the appointment, the brief profile of the appointee, and disclosure of relationships between directors. There is no financial data, earnings information, or report publication mentioned. The document fits the description of an announcement of changes in the company's board or senior management, which corresponds to the category 'Board/Management Information' (MANG). The document length is 2846 characters, which is typical for such announcements and not a full report. Therefore, the classification is MANG with high confidence.
2025-09-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.